Holen Sie sich die Stockscreener-App
24.54
0.77%
-0.19
Handel nachbörslich:
24.52
-0.02
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.73
Offen:
$24.65
24-Stunden-Volumen:
38.86M
Relative Volume:
0.81
Marktkapitalisierung:
$139.41B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.05
EPS:
1.8799
Netto-Cashflow:
$12.44B
1W Leistung:
-6.59%
1M Leistung:
+2.81%
6M Leistung:
+10.94%
1J Leistung:
-15.61%
1-Tages-Spanne:
$24.48
$24.79
1-Wochen-Bereich:
$24.48
$26.50
52-Wochen-Spanne:
$20.91
$29.82
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.52 | 140.60B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
812.37 | 734.56B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.81 | 459.75B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
229.18 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.27 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.70 | 214.06B | 63.43B | 16.42B | 14.72B | 6.4861 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer's (PFE) Tukysa Achieves Key Milestone in Breast Cancer Tr - GuruFocus
Pfizer (PFE) Receives a Hold from Bernstein - The Globe and Mail
Pfizer posts late-stage trial win for cancer drug (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Positive Results from Key Breast Cancer Tri - GuruFocus
Pfizer Says Tukysa Combination as First-Line Maintenance Meets Main Goal in Breast Cancer Trial - MarketScreener
Tukysa combination significantly improves progression-free survival as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial - MarketScreener
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewswire Inc.
Pfizer’s breast cancer drug shows promise in first-line treatment - Investing.com
Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] - Trefis
Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock - Yahoo Finance
Trump's AstraZeneca Deal Echoes Pfizer Pact. Big Pharma's Political Headaches Are Easing. - Barron's
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs - Contract Pharma
Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot - Truthout
Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Medical Daily
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Pfizer stock rises as BMO Capital reiterates Outperform rating - Investing.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
Verdence Capital Advisors LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer To Highlight Advancements In Respiratory Health And Infectious Disease Research At IDWeek 2025 - TradingView
Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer to present infectious disease data at IDWeek 2025 - Investing.com
Concurrent Investment Advisors LLC Purchases 20,663 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 - Business Wire
Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. (PFE) Stock Analysis: Exploring the 16% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Estrogen Blockers Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com
IP Group in line for future royalties from Pfizer’s drug deal - Proactive Investors
FY2025 EPS Estimates for Pfizer Lowered by Cantor Fitzgerald - MarketBeat
Is Pfizer (NYSE:PFE) Using Too Much Debt? - Yahoo Finance
Cwm LLC Raises Stake in Pfizer Inc. $PFE - MarketBeat
Sippican Capital Advisors Has $2.25 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Means Investment CO. Inc. Sells 22,379 Shares of Pfizer Inc. $PFE - MarketBeat
Callan Family Office LLC Purchases 48,269 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025) - 24/7 Wall St.
Pfizer (PFE) Faces Challenges Amid Drug Pricing Push - GuruFocus
LaRuby May and team of attorneys file suit against Pfizer, claim negligence in premature release of sickle cell drug therapy - AFRO American Newspapers
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Deal on Drug Prices Gets Closer to the Right Idea - Advisor Perspectives
Guggenheim Keeps Their Buy Rating on Pfizer (PFE) - The Globe and Mail
Pfizer Inc. $PFE Shares Bought by Fifth Third Wealth Advisors LLC - MarketBeat
Drucker Wealth 3.0 LLC Sells 15,443 Shares of Pfizer Inc. $PFE - MarketBeat
Aberdeen Group plc Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Pfizer (NYSE:PFE) Trading Down 1.7%What's Next? - MarketBeat
Pfizer (PFE) Target Price Lowered by Morgan Stanley | PFE Stock News - GuruFocus
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - WHTC
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta - GuruFocus
Sandoz granted tentative approval for generic of Pfizer's Inlyta - Seeking Alpha
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):